Suraev Anastasia, Mills Llewellyn, Abelev Sarah V, Arkell Thomas R, Lintzeris Nicholas, McGregor Iain S
The University of Sydney, Lambert Initiative for Cannabinoid Therapeutics, Sydney, NSW, Australia.
The University of Sydney, Faculty of Science, School of Psychology, Sydney, NSW, Australia.
Nat Sci Sleep. 2023 Apr 17;15:245-255. doi: 10.2147/NSS.S390583. eCollection 2023.
Sleep disorders are the third most common indication for the prescription of medical cannabis products in Australia, after pain and anxiety. While the use of cannabis for medical purposes is growing in Australia, underlying consumer behaviours and patterns of use, particularly around sleep disorders, are poorly understood.
We conducted a subanalysis of the cross-sectional "Cannabis as Medicine Survey" 2020-2021 (CAMS-20) (N = 1600), to explore the characteristics of a sample of Australians who were using prescribed and/or illicit medical cannabis to treat a self-reported sleep disorder.
When asked to specify up to seven different conditions they were treating with medical cannabis, a total of 1030 (64%) respondents [mean (SD) 44.9 (13.6) years] selected a sleep disorder, with "insomnia disorder" (85.5%), 'sleep-related movement disorders' (26%) and 'sleep-related breathing disorders' (11.1%) the most common subtypes. Only 165 (16.8%) respondents selected a self-reported sleep disorder as the main health condition being treated. Relative to other health conditions, use of medical cannabis for a self-reported sleep disorder was associated with younger age, increased likelihood of using both prescribed and illicit forms of medical cannabis, inhaled routes of administration, and THC-dominant products. Most respondents reported a reduction in the use of benzodiazepines and alcohol since starting medical cannabis. Binary logistic regression showed that respondents who predominantly used inhaled routes of administration, and concomitant use of medical cannabis for pain, mental health and/or substance use disorder, or a gastrointestinal disorder, were significantly more likely to also use medical cannabis to treat a self-reported sleep disorder.
Overall, these results suggest that self-reported sleep disorders are often being treated with medical cannabis alongside other health conditions (often pain or a mental health disorder) and that use of inhaled methods, THC-dominant products, and illicit sources of medical cannabis are common among people with self-reported sleep disorders in Australia.
在澳大利亚，睡眠障碍是继疼痛和焦虑之后，开具医用大麻产品处方的第三大常见适应症。虽然医用大麻在澳大利亚的使用正在增加，但人们对潜在的消费者行为和使用模式，尤其是围绕睡眠障碍的行为和模式了解甚少。
我们对2020 - 2021年的横断面“医用大麻调查”（CAMS - 20）（N = 1600）进行了子分析，以探究使用处方和/或非法医用大麻治疗自我报告睡眠障碍的澳大利亚样本的特征。
当被要求具体列出他们使用医用大麻治疗的多达七种不同病症时，共有1030名（64%）受访者[平均（标准差）44.9（13.6）岁]选择了睡眠障碍，其中“失眠症”（85.5%）、“睡眠相关运动障碍”（26%）和“睡眠相关呼吸障碍”（11.1%）是最常见的亚型。只有165名（16.8%）受访者选择自我报告的睡眠障碍作为正在治疗的主要健康状况。相对于其他健康状况，使用医用大麻治疗自我报告的睡眠障碍与年龄较小、使用处方和非法形式医用大麻的可能性增加、吸入给药途径以及以四氢大麻酚为主的产品有关。大多数受访者报告自开始使用医用大麻以来，苯二氮䓬类药物和酒精的使用量有所减少。二元逻辑回归显示，主要使用吸入给药途径、同时使用医用大麻治疗疼痛、心理健康和/或物质使用障碍或胃肠道疾病的受访者，也更有可能使用医用大麻治疗自我报告的睡眠障碍。
总体而言，这些结果表明，自我报告的睡眠障碍通常与其他健康状况（通常是疼痛或心理健康障碍）一起使用医用大麻进行治疗，并且在澳大利亚自我报告有睡眠障碍的人群中，使用吸入方法、以四氢大麻酚为主的产品以及非法来源的医用大麻很常见。
